Sprint Corporation (NYSE: S) announced today that it has signed three
new vendor financing facilities totaling $1.8 billion to purchase 2.5
GHz network equipment and related services from key suppliers.
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine
platform company developing targeted and programmable therapeutics
called Accurins TM , announced today that it has entered into
an amendment of its existing credit facility from Hercules Technology
III, L.P., an affiliate of Hercules Technology Growth Capital (NYSE:
HTCG). Under the amendment, the company borrowed an additional $15
million in growth capital, less the repayment of the outstanding balance
on BIND’s existing term loan facility of approximately $3 million.
- Revenue: $567 million - Gross Margin: 55.4% GAAP (60.3% excluding special items) - EPS: $0.25 GAAP loss ($0.33 profit excluding special items)
- Cash, cash equivalents, and short term investments: $1.38 billion - Fiscal second quarter revenue outlook: $565 million to $605 million SAN JOSE, Calif.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.